Who are Delphi Diagnostics's investors?

Delphi Diagnostics's investors include aVenture, DigitalDx Ventures.

How much funding has Delphi Diagnostics raised?

Delphi Diagnostics has disclosed $470K raised across 1 of its 2 known rounds.

Where is Delphi Diagnostics headquartered?

Delphi Diagnostics is headquartered in Austin, US.

Delphi Diagnostics

Austin, US · Founded 2016 · Texas corporation · 2 known investors

Delphi Diagnostics develops genomic diagnostic tests for breast cancer that measure endocrine transcriptional activity to help healthcare providers personalize treatment decisions. Its tests target Stage II-III, HR+, HER2- breast cancer patients to identify who will benefit from dose-intense chemotherapy and to inform recurrence risk and prognosis.

Biotech Healthtech

Founders & leadership

William CreechExecutive

Investors · 2

aVentureSan Francisco

DigitalDx VenturesMenlo Park

Reported raises · per SEC filings

Form D private placements

$470K disclosed across 1 of 2 rounds · 2017–2021

▶$50MofferedJun 2021 · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Winz CasagrandeExecutive Officer, Director
Fidel ReijerseDirector
Paul SmithDirector

Offering amount: $50M
Incorporated: Corporation, Texas, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$470KraisedJan 2017 · 3 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

William CreechExecutive Officer

Offering amount: $1M
Amount sold: $470K
First sale: Jan 2017
Incorporated: Corporation, Texas, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

Delphi6 shared keywordsDelphi is an AI-powered assistant platform that helps venture capitalists scale their investment operations by automating deal screening, founder communication, and thought leadership distribution. The platform trains on a VC's own content and investment thesis to provide personalized feedback to founders and manage deal flow 24/7.

Delfi Diagnostics6 shared keywordsDELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening. The test offers an alternative to low-dose CT imaging for patients meeting USPSTF criteria and is made available to health systems, primary care providers, and lung screening programs.

Delphia Therapeutics5 shared keywordsDelphia Therapeutics is a biotechnology company developing cancer medicines based on its activation lethality platform, aiming to create therapies effective on their own while combating resistance to targeted therapies. It focuses on oncology drug discovery and clinical development.

Companies competing with Delphi Diagnostics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Investors - Delphi Diagnosticsdelphi-diagnostics.com · Apr 2025

Frequently asked questions

What does Delphi Diagnostics do?: Delphi Diagnostics develops genomic diagnostic tests for breast cancer that measure endocrine transcriptional activity to help healthcare providers personalize treatment decisions. Its tests target Stage II-III, HR+, HER2- breast cancer patients to identify who will benefit from dose-intense chemotherapy and to inform recurrence risk and prognosis.
Who are Delphi Diagnostics's investors?: Delphi Diagnostics's investors include aVenture, DigitalDx Ventures.
How much funding has Delphi Diagnostics raised?: Delphi Diagnostics has disclosed $470K raised across 1 of its 2 known rounds.
Where is Delphi Diagnostics headquartered?: Delphi Diagnostics is headquartered in Austin, US.